DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Otamixaban
Otamixaban
Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
Heparin EDTA Patent Application Publication Feb
Study Protocol
(12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher Et Al
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Current Clinical Evidence and Future Developments
(10) Patent No.: US 9034822 B2
What Is/Are the Best Oral Anticoagulant/S for Primary Prevention, Treatment
Stembook 2018.Pdf
Head Injury Partial Update
Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-Cov-2 Into
Evidence-Based College of Chest Physicians New Antithrombotic Drugs
(10) Patent No.: US 9062298 B2
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Indirect and Direct Anticoagulants Predominantly Inhibiting Factor Xa
Thromboseprophylaxe Mit Xabanen
Molecular Recognition at the Active Site of Factor Xa
Pharmaceutical Clinical Trials in New York in State Taxes and More Than $646 Million in Federal • Clinical Trials Are Responsible for 45 to 75 Percent of Taxation
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds S
Top View
Pharmaceutical Compositions Comprising Prasugrel And
Pharmaabkommen A1 E
State of the Art in Hospital Management of Non-ST-Elevation
Competitive Outlook Takes Its Toll on Merck and Portola's Factor Xa Inhibitor
The Fight Against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?
Customs Tariff - Schedule Xxi - 1
To High-Risk Patients with Non-ST Elevation Acute Coronary
Sokestrategi PICO 1.4 Dokument
(12) Patent Application Publication (10) Pub. No.: US 2012/0252852 A1 KAMM Et Al
Anticoagulation with Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: the TAO Randomized Clinical Trial
C. Noah Israel MD, F.A.C.C
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
KEY LEARNINGS from OTAMIXABAN DEVELOPMENT Christophe Gaudin, MD* Head of Development, Cardiovascular and Fibrosis Unit Sanofi R&D
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Downloaded from Drugbank [21], Pdbe [45], Or Chemspider [46]
Synergistic Inhibition of SARS-Cov-2 Cell Entry by Otamixaban and Covalent Protease Inhibitors: Pre- Cite This: DOI: 10.1039/D1sc01494c
(12) Patent Application Publication (10) Pub. No.: US 2014/0296257 A1 Hersel Et Al
Parenteral Anticoagulants in Heart Disease: Current Status And
Novel Sulfated 4-Hydroxycinnamic Acid Oligomers As Potent Anticoagulants
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Drug Repurposing Compound Library (96-Well)
Cardiovascular Disease
Anticoagulants for Acute Ischaemic Stroke (Review)
Development of New Anticoagulants: Present and Future
Identification of Potential Drug Targets Based on a Computational Biology Algorithm for Venous Thromboembolism
WO 2012/170676 Al 13 December 2012 (13.12.2012) P O P C T
Otamixaban for Non-ST Elevation Acute Coronary Syndrome (NSTE
Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
Learningpharmacology 2018.Pdf